This review discusses the significance of the FDA-approved drug inotuzumab ozogamicin in pediatric patients with acute lymphocytic leukemia (ALL) and relapsed/refractory (R/R) ALL, and the evolving therapeutic options in R/R ALL.
Basmah Zahid, PharmD, MS
Advertisement
Articles by Basmah Zahid, PharmD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
3
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
4
Recognizing Immunizing Pharmacists in the Community
5
